Natixis Advisors LLC Has $13.83 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Natixis Advisors LLC increased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 24.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 41,323 shares of the medical research company's stock after buying an additional 8,077 shares during the quarter. Natixis Advisors LLC owned 0.15% of Bio-Rad Laboratories worth $13,826,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BIO. Capital Advisors Ltd. LLC lifted its holdings in shares of Bio-Rad Laboratories by 193.8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock valued at $26,000 after purchasing an additional 62 shares in the last quarter. UMB Bank n.a. increased its position in shares of Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock worth $26,000 after acquiring an additional 45 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth $51,000. Headlands Technologies LLC bought a new stake in Bio-Rad Laboratories in the 2nd quarter valued at $51,000. Finally, Quarry LP acquired a new position in Bio-Rad Laboratories in the 2nd quarter worth $59,000. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Stock Performance

Shares of Bio-Rad Laboratories stock traded up $2.30 during trading on Thursday, hitting $325.99. 113,975 shares of the stock were exchanged, compared to its average volume of 246,192. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The company has a fifty day moving average price of $340.38 and a 200-day moving average price of $315.33. The stock has a market capitalization of $9.13 billion, a price-to-earnings ratio of -11.93 and a beta of 0.93. Bio-Rad Laboratories, Inc. has a 1-year low of $262.12 and a 1-year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.85. The firm had revenue of $649.70 million for the quarter, compared to analyst estimates of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The business's revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.33 earnings per share. As a group, equities analysts predict that Bio-Rad Laboratories, Inc. will post 9.93 EPS for the current fiscal year.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares of the company's stock, valued at approximately $48,582.03. This trade represents a 80.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Andrew J. Last sold 3,000 shares of the company's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the transaction, the chief operating officer now owns 7,559 shares in the company, valued at $2,494,016.46. This trade represents a 28.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on BIO. Wells Fargo & Company began coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price target on the stock. Royal Bank of Canada upped their price target on Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Citigroup lifted their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Finally, StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $391.80.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.